meningococcal ACWY conjugate vaccine + pneumococcal conjugate vaccine 13-valent

This combination refers to the co-administration of the quadrivalent meningococcal conjugate vaccine (MenACWY) and the 13-valent pneumococcal conjugate vaccine (PCV13). MenACWY vaccines, such as Menveo, Nimenrix, and MenQuadfi, provide protection against *Neisseria meningitidis* serogroups A, C, W, and Y, which are major causes of bacterial meningitis and septicemia. PCV13, marketed as Prevnar 13, targets 13 serotypes of *Streptococcus pneumoniae* (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) responsible for invasive pneumococcal disease, pneumonia, and otitis media. Both vaccines utilize conjugation technology, where bacterial capsular polysaccharides are chemically linked to a carrier protein (typically CRM197 or tetanus toxoid) to convert the T-cell independent polysaccharide antigens into T-cell dependent antigens, thereby inducing immunological memory and high antibody titers in infants and young children. They are frequently administered concomitantly during routine pediatric vaccination visits.

Brand names

Prevnar 13Prevnar13Prevnar-13MenveoMenQuadfiNimenrixMenactra

Other names

MenACWY + PCV13meningococcal group A, C, W135, and Y conjugate vaccine + pneumococcal 13-valent conjugate vaccine